Kabadi U M, Cech R
VA Medical Centers, Des Moines Iowa, USA.
J Endocrinol Invest. 1997 Jun;20(6):319-26. doi: 10.1007/BF03350310.
The natural course in subjects manifesting normal serum thyroxine (T4), and triiodothyronine (T3), with an elevated thyrotropin (TSH) level demonstrated two distinct outcomes, one progressing to well defined hypothyroidism as expressed by onset of subnormal T4, T3 and a further rise in TSH and the other remaining in the same state. However, thyroid hormone concentrations at the time of diagnosis fail to distinguish between the two groups. Therefore, we examined the influence of alteration in circulating TSH levels on thyroid gland function at the time of diagnosis in subjects with this syndrome to assess the role of pituitary thyroid axis in these different outcomes.
24 hour 131I thyroidal uptake was determined in 14 men and 3 women manifesting normal T4, T3 and elevated TSH prior to and again after 1) subcutaneous administration of bovine TSH, 10 units daily for 3 days and 2) daily oral administration of L-triiodothyronine 75 micrograms for 7 days in a randomized sequence at interval of 4 weeks. Subjects were then followed for up to 16 years to assess the natural course.
Basal 24 hour 131I uptake values were within the normal range (10-35%) in all subjects and increased on TSH administration and declined following LT3 administration. However, in eight subjects, these responses were markedly lower (< 20%) when compared with the minimum change (50%) noted in normal volunteers. These subjects progressed to manifest hypothyroidism requiring LT4 therapy within two years as reflected by a progressive decrease to subnormal T4 levels with a further rise in serum TSH. The remaining nine subjects, demonstrated normal responses (> 50%) and only one of these became hypothyroid during the follow-up period of 16 years.
All subjects with normal T4 and T3 with elevated TSH do not manifest "subclinical or evolving hypothyroidism". Two distinct populations seem to exist, one with inhibited pituitary thyroid axis progressing to hypothyroidism or true "subclinical hypothyroidism" at the time of diagnosis and the other with normal pituitary thyroid axis, a state of euthyroidism with "reset thyrostat" at a higher TSH concentration, a state probably persisting for their remaining life span.
血清甲状腺素(T4)和三碘甲状腺原氨酸(T3)正常但促甲状腺激素(TSH)水平升高的患者,其自然病程呈现出两种不同的结果,一种发展为明确的甲状腺功能减退,表现为T4、T3低于正常水平且TSH进一步升高,另一种则维持在相同状态。然而,诊断时的甲状腺激素浓度无法区分这两组患者。因此,我们研究了患有该综合征的患者在诊断时循环TSH水平变化对甲状腺功能的影响,以评估垂体 - 甲状腺轴在这些不同结果中的作用。
对14名男性和3名女性进行研究,这些患者T4、T3正常但TSH升高。在以下两种情况下,分别于给药前及给药后再次测定24小时131I甲状腺摄取率:1)皮下注射牛TSH,每日10单位,共3天;2)每日口服L - 三碘甲状腺原氨酸75微克,共7天,两种给药方式按随机顺序进行,间隔4周。然后对患者进行长达16年的随访,以评估其自然病程。
所有受试者的基础24小时131I摄取率值均在正常范围内(10 - 35%),注射TSH后升高,服用L - T3后下降。然而,与正常志愿者中观察到的最小变化(50%)相比,8名受试者的这些反应明显较低(< 20%)。这些受试者在两年内发展为需要L - T4治疗的甲状腺功能减退,表现为T4水平逐渐降至低于正常,同时血清TSH进一步升高。其余9名受试者表现出正常反应(> 50%),在16年的随访期内只有1人发展为甲状腺功能减退。
所有T4、T3正常但TSH升高的患者并非都表现为“亚临床或进展性甲状腺功能减退”。似乎存在两个不同的群体,一个群体在诊断时垂体 - 甲状腺轴受到抑制,进展为甲状腺功能减退或真正的“亚临床甲状腺功能减退”,另一个群体垂体 - 甲状腺轴正常,处于甲状腺功能正常状态,甲状腺调节机制在较高TSH浓度下“重置”,这种状态可能会持续其余生。